Genomic variations in plasma cell free DNA differentiate early stage lung cancers from normal controls

Lung Cancer

Volumn 90, Issue 1, 2015, Pages 78-84

  Xia, Shu ^a,b   Huang, Chiang Ching ^c   Le, Min ^b   Dittmar, Rachel ^b   Du, Meijun ^b   Yuan, Tiezheng ^b   Guo, Yongchen ^b   Wang, Yuan ^b   Wang, Xuexia ^c   Tsai, Susan ^b   Suster, Saul ^b   Mackinnon, Alexander C ^b   Wang, Liang ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c UNIVERSITY OF WISCONSIN MILWAUKEE   (United States)

Author keywords

Allele specific PCR; CfDNA; Copy number variations; Digital PCR; Next generation sequencing; Non small cell lung cancer; Plasma

Indexed keywords

ATM PROTEIN; CELL DNA; CELL FREE TUMOR DNA; DNA FRAGMENT; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 2; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; K RAS PROTEIN; NOTCH1 RECEPTOR; OXYGEN; PROTEIN KINASE LKB1; PROTEIN P53; UNCLASSIFIED DRUG; DNA; TUMOR MARKER;

ADULT; AGED; ALLELE; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER TISSUE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA CONTENT; DNA EXTRACTION; EARLY CANCER; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENE TARGETING; GENETIC ALGORITHM; GENETIC VARIABILITY; GENOMICS; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG PARENCHYMA; MALE; MIDDLE AGED; MUTATIONAL ANALYSIS; PLASMA; PLASMA CELL; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEX CHROMOSOME; TUMOR GENE; VERY ELDERLY; ADENOCARCINOMA; BLOOD; CASE CONTROL STUDY; DEVICES; DNA MUTATIONAL ANALYSIS; GENETIC VARIATION; GENETICS; HIGH THROUGHPUT SEQUENCING; LUNG TUMOR; METABOLISM; MUTATION; PATHOLOGY; PROCEDURES;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; DNA COPY NUMBER VARIATIONS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GENETIC VARIATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PLASMA CELLS; POLYMERASE CHAIN REACTION;

EID: 84940955516     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.07.002     Document Type: Article

References (35)

1. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J. Clin. 2014, 64(1):9-29.
2. Howlader N NA, Krapcho M, et al. SEER Cancer Statistics Review In: National Cancer Institute. vol. 1975-2009 (Vintage 2009 Populations) based on November 2011 SEER data submission, 1975-2009 (Vintage 2009 Populations) based on November 2011 SEER data submission. edn: Bethesda, MD; 2012.
3. Heuvers M.E., Hegmans J.P., Stricker B.H., Aerts J.G. Improving lung cancer survival; time to move on. BMC Pulm. Med. 2012, 12:77.
4. Aberle D.R., Adams A.M., Berg C.D., Black W.C., Clapp J.D., Fagerstrom R.M., Gareen I.F., Gatsonis C., Marcus P.M., Sicks J.D. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med. 2011, 365(5):395-409.
5. Patz E.F., Pinsky P., Gatsonis C., Sicks J.D., Kramer B.S., Tammemagi M.C., Chiles C., Black W.C., Aberle D.R. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern. Med. 2014, 174(2):269-274.
6. Takiguchi Y., Sekine I., Iwasawa S. Overdiagnosis in lung cancer screening with low-dose computed tomography. J. Thorac. Oncol. 2013, 8(11):e101-e102.
7. Negrini S., Gorgoulis V.G., Halazonetis T.D. Genomic instability-an evolving hallmark of cancer. Nat. Rev. Mol. Cell Biol. 2010, 11(3):220-228.
8. Kaiser Medicine J. Keeping tabs on tumor DNA. Science 2010, 327(5969):1074.
9. Catarino R., Coelho A., Araujo A., Gomes M., Nogueira A., Lopes C., Medeiros R. Circulating DNA diagnostic tool and predictive marker for overall survival of NSCLC patients. PLoS One 2012, 7(6):e38559.
10. van der Drift M.A., Hol B.E., Klaassen C.H., Prinsen C.F., van Aarssen Y.A., Donders R., van der Stappen J.W., Dekhuijzen P.N., van der Heijden H.F., Thunnissen F.B. Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer. Lung Cancer 2010, 68(2):283-287.
11. Sirera R., Bremnes R.M., Cabrera A., Jantus-Lewintre E., Sanmartin E., Blasco A., Del Pozo N., Rosell R., Guijarro R., Galbis J., et al. Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer. J. Thorac. Oncol. 2011, 6(2):286-290.
12. Dawson S.J., Tsui D.W., Murtaza M., Biggs H., Rueda O.M., Chin S.F., Dunning M.J., Gale D., Forshew T., Mahler-Araujo B., et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 2013, 368(13):1199-1209.
13. Murtaza M., Dawson S.J., Tsui D.W., Gale D., Forshew T., Piskorz A.M., Parkinson C., Chin S.F., Kingsbury Z., Wong A.S., et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013, 497(7447):108-112.
14. Leary R.J., Sausen M., Kinde I., Papadopoulos N., Carpten J.D., Craig D., O'Shaughnessy J., Kinzler K.W., Parmigiani G., Vogelstein B., et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci. Transl. Med. 2012, 4(162). 162ra154.
15. Xia S., Kohli M., Du M., Dittmar R.L., Lee A., Nandy D., Yuan T., Guo Y., Wang Y., Tschannen M.R. Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer. Oncotarget 2015.
16. Ni X., Zhuo M., Su Z., Duan J., Gao Y., Wang Z., Zong C., Bai H., Chapman A.R., Zhao J., et al. Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients. Proc. Natl. Acad. Sci. U S A 2013, 110(52):21083-21088.
17. Shaw J.A., Page K., Blighe K., Hava N., Guttery D., Ward B., Brown J., Ruangpratheep C., Stebbing J., Payne R., et al. Genomic analysis of circulating cell-free DNA infers breast cancer dormancy. Genome Res. 2012, 22(2):220-231.
18. Heitzer E., Ulz P., Belic J., Gutschi S., Quehenberger F., Fischereder K., Benezeder T., Auer M., Pischler C., Mannweiler S., et al. Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. Genome Med. 2013, 5(4):30.
19. Narayan A., Carriero N.J., Gettinger S.N., Kluytenaar J., Kozak K.R., Yock T.I., Muscato N.E., Ugarelli P., Decker R.H., Patel A.A. Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing. Cancer Res. 2012, 72(14):3492-3498.
20. Rai A.J., Gelfand C.A., Haywood B.C., Warunek D.J., Yi J., Schuchard M.D., Mehigh R.J., Cockrill S.L., Scott G.B., Tammen H., et al. HUPO plasma proteome project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics 2005, 5(13):3262-3277.
21. Diskin S.J., Li M., Hou C., Yang S., Glessner J., Hakonarson H., Bucan M., Maris J.M., Wang K. Adjustment of genomic waves in signal intensities from whole-genome SNP genotyping platforms. Nucleic Acids Res. 2008, 36(19):e126.
22. Schwarzenbach H., Hoon D.S., Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 2011, 11(6):426-437.
23. Garcia-Olmo D.C., Dominguez C., Garcia-Arranz M., Anker P., Stroun M., Garcia-Verdugo J.M., Garcia-Olmo D. Cell-free nucleic acids circulating in the plasma of colorectal cancer patients induce the oncogenic transformation of susceptible cultured cells. Cancer Res. 2010, 70(2):560-567.
24. Zhou J., Shi Y.H., Fan J. Circulating cell-free nucleic acids: promising biomarkers of hepatocellular carcinoma. Semin. Oncol. 2012, 39(4):440-448.
25. Heitzer E., Auer M., Hoffmann E.M., Pichler M., Gasch C., Ulz P., Lax S., Waldispuehl-Geigl J., Mauermann O., Mohan S., et al. Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer. Int. J. Cancer 2013, 133(2):346-356.
26. Chan K.C., Jiang P., Zheng Y.W., Liao G.J., Sun H., Wong J., Siu S.S., Chan W.C., Chan S.L., Chan A.T., et al. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin. Chem. 2013, 59(1):211-224.
27. Iafrate A.J., Feuk L., Rivera M.N., Listewnik M.L., Donahoe P.K., Qi Y., Scherer S.W., Lee C. Detection of large-scale variation in the human genome. Nat. Genet. 2004, 36(9):949-951.
28. Forshew T., Murtaza M., Parkinson C., Gale D., Tsui D.W., Kaper F., Dawson S.J., Piskorz A.M., Jimenez-Linan M., Bentley D., et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci. Transl. Med. 2012, 4(136). 136ra168.
29. Beaver J.A., Jelovac D., Balukrishna S., Cochran R.L., Croessmann S., Zabransky D.J., Wong H.Y., Valda Toro P., Cidado J., Blair B.G., et al. Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin. Cancer Res. 2014, 20(10):2643-2650.
30. Oxnard G.R., Paweletz C.P., Kuang Y., Mach S.L., O'Connell A., Messineo M.M., Luke J.J., Butaney M., Kirschmeier P., Jackman D.M., et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin. Cancer Res. 2014, 20(6):1698-1705.
31. Diaz L.A., Williams R.T., Wu J., Kinde I., Hecht J.R., Berlin J., Allen B., Bozic I., Reiter J.G., Nowak M.A., et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012, 486(7404):537-540.
32. Bettegowda C., Sausen M., Leary R.J., Kinde I., Wang Y., Agrawal N., Bartlett B.R., Wang H., Luber B., Alani R.M., et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 2014, 6(224). 224ra224.
33. Perkins G., Yap T.A., Pope L., Cassidy A.M., Dukes J.P., Riisnaes R., Massard C., Cassier P.A., Miranda S., Clark J., et al. Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers. PLoS One 2012, 7(11):e47020.
34. Chan K.C., Jiang P., Zheng Y.W., Liao G.J., Sun H., Wong J., Siu S.S., Chan W.C., Chan S.L., Chan A.T., et al. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin. Chem. 2013, 59(1):211-224.
35. Newman A.M., Bratman S.V., To J., Wynne J.F., Eclov N.C., Modlin L.A., Liu C.L., Neal J.W., Wakelee H.A., Merritt R.E., et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat. Med. 2014, 20(5):548-554.